{"ok":true,"entry":{"slug":"testosterone","kind":"medication","name":"testosterone","aliases":["Nebido","Androgel","testosterone undecanoate"],"brands_sg":["Nebido","Androgel","Sustanon 250","Depo-Testosterone"],"class":"androgen","tags":["hormonal"],"use_for":"replacement in confirmed male hypogonadism","use_after":"sg labels: gel once daily; nebido every 10 to 14 weeks","use_duration":null,"take_with":"not oral in sg — gel on shoulders and arms, or injection","pros":["sg label: gel dose set by morning blood testosterone","nebido label: one injection covers 10 to 14 weeks","four sg brands: one gel and three injections"],"cons":["label: contraindicated in prostate or breast cancer","gel can transfer to others through skin contact","label: not for use in women, or in males under 18"],"dose_note":"two sg labels, two different ceilings. the androgel 16.2 mg/g label says the daily dose is adjusted \"not exceeding four pump actuations or 81 mg testosterone per day\", with treatment stopped if levels stay low \"at the highest dose of 81 mg (5 g gel, i.e. four pump actuations)\". the nebido label instead sets an interval: \"Nebido (1 ampoule / vial corresponding to 1000 mg testosterone undecanoate) is injected every 10 to 14 weeks\", and \"the first injection interval may be reduced to a minimum of 6 weeks\" — as directed on the label or by your doctor","dosage":null,"ul_status":null,"sg_class":"prescription-only","cautions":["prostate cancer or male breast cancer, confirmed or suspected — a contraindication on both sg labels","past or present liver tumours, and high blood calcium from a tumour — nebido label contraindications","women — the sg nebido label states that use in women is contraindicated, and the androgel label covers adult men only","under 18 — nebido is not indicated in children and adolescents; androgel safety in boys under 18 is not established"],"clashes":[{"src":["fda_testo_int"],"note":"us label: androgens may decrease blood glucose and therefore may decrease insulin requirements in diabetic patients","with":"insulin and other diabetes medicines"},{"src":["fda_testo_int","fda_testo_cyp_int"],"note":"us label: changes in anticoagulant activity may be seen; more frequent inr and prothrombin monitoring is recommended","with":"oral anticoagulants such as warfarin"},{"src":["fda_testo_int"],"note":"us label: concurrent use may result in increased fluid retention, especially with cardiac, renal or hepatic disease","with":"corticosteroids or acth"},{"src":["fda_testo_cyp_int"],"note":"us testosterone cypionate label: concurrent use may result in elevated serum levels of oxyphenbutazone","with":"oxyphenbutazone"}],"sources":[{"id":"hsa_register","url":"https://data.gov.sg/api/action/datastore_search?resource_id=d_767279312753558cbf19d48344577084&limit=6000","label":"HSA — Listing of Registered Therapeutic Products (data.gov.sg d_767279312753558cbf19d48344577084), Forensicclassification column; cached at /tmp/hsa_all.json and filtered locally, not re-fetched","quote":"NEBIDO Solution SIN13281P | Testosterone undecanoate | Prescription Only | G03BA03; ANDROGEL GEL 16.2MG/G SIN16857P; Androgel 25mg SIN13161P; Androgel 50mg SIN13162P; SUSTANON 250 INJECTION SIN04555P; DEPO-TESTOSTERONE 100 mg/ml SIN04518P — all 6 testosterone rows Prescription Only","accessed":"2026-08-27"},{"id":"ndf_nebido","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin13281p/","label":"MOH National Drug Formulary (Singapore) — NEBIDO Solution [SIN13281P], product information","quote":"TESTOSTERONE UNDECANOATE - 1,000 MG/4 ML … Forensic Classification PRESCRIPTION ONLY MEDICINES … Anatomical Therapeutic Chemical (ATC) code G03BA03 … Prescription-only Medicines with Exemptions for Supply without Prescription NA","accessed":"2026-08-27"},{"id":"ndf_nebido_ind","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin13281p/","label":"MOH National Drug Formulary (Singapore) — NEBIDO [SIN13281P], 4.1 Indication(s)","quote":"Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests","accessed":"2026-08-27"},{"id":"ndf_nebido_dose","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin13281p/","label":"MOH National Drug Formulary (Singapore) — NEBIDO [SIN13281P], 4.2 Dosage and method of administration","quote":"Nebido (1 ampoule / vial corresponding to 1000 mg testosterone undecanoate) is injected every 10 to 14 weeks … the first injection interval may be reduced to a minimum of 6 weeks","accessed":"2026-08-27"},{"id":"ndf_nebido_ci","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin13281p/","label":"MOH National Drug Formulary (Singapore) — NEBIDO [SIN13281P], 4.3 Contraindications","quote":"Androgen-dependent carcinoma of the prostate or of the male mammary gland Hypercalcemia accompanying malignant tumours Past or present liver tumours … The use of Nebido in women is contraindicated.","accessed":"2026-08-27"},{"id":"ndf_nebido_paed","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin13281p/","label":"MOH National Drug Formulary (Singapore) — NEBIDO [SIN13281P], paediatric patients","quote":"Nebido is not indicated for use in children and adolescents and it has not been clinically evaluated in males under 18 years of age","accessed":"2026-08-27"},{"id":"ndf_androgel","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin16857p/","label":"MOH National Drug Formulary (Singapore) — ANDROGEL GEL 16.2MG/G [SIN16857P], product information","quote":"TESTOSTERONE - 1.62 G/100 G … Forensic Classification PRESCRIPTION ONLY MEDICINES … Anatomical Therapeutic Chemical (ATC) code G03BA03 … Prescription-only Medicines with Exemptions for Supply without Prescription NA","accessed":"2026-08-27"},{"id":"ndf_androgel_ind","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin16857p/","label":"MOH National Drug Formulary (Singapore) — ANDROGEL 16.2 mg/g [SIN16857P], Indication","quote":"ANDROGEL 16.2 mg/g gel is indicated in adults as replacement therapy for male hypogonadism when testosterone deficiency has been clinically and biologically confirmed.","accessed":"2026-08-27"},{"id":"ndf_androgel_dose","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin16857p/","label":"MOH National Drug Formulary (Singapore) — ANDROGEL 16.2 mg/g [SIN16857P], Recommended Dosage","quote":"The recommended dose is two pump actuations (i.e. 40.5 mg of testosterone) applied once daily … not exceeding four pump actuations or 81 mg testosterone per day","accessed":"2026-08-27"},{"id":"ndf_androgel_dose2","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin16857p/","label":"MOH National Drug Formulary (Singapore) — ANDROGEL 16.2 mg/g [SIN16857P], Recommended Dosage: stopping rule at the highest dose","quote":"if normal blood testosterone levels are not achieved at the highest dose of 81 mg (5 g gel, i.e. four pump actuations)","accessed":"2026-08-27"},{"id":"ndf_androgel_admin","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin16857p/","label":"MOH National Drug Formulary (Singapore) — ANDROGEL 16.2 mg/g [SIN16857P], Mode of Administration","quote":"The application should be done by the patient himself, on clean, dry and healthy skin, on the right and left shoulders and upper arms … Wash the application site thoroughly with soap and water","accessed":"2026-08-27"},{"id":"ndf_androgel_ci","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin16857p/","label":"MOH National Drug Formulary (Singapore) — ANDROGEL 16.2 mg/g [SIN16857P], Contraindications","quote":"ANDROGEL 16.2 mg/g, gel is contraindicated: in case of confirmed or suspected prostate cancer or breast carcinoma in case of hypersensitivity to the active ingredient or to any of the excipients.","accessed":"2026-08-27"},{"id":"fda_testo_int","url":"https://api.fda.gov/drug/label.json?search=openfda.substance_name:%22TESTOSTERONE%22+AND+_exists_:drug_interactions&limit=3","label":"US FDA label — testosterone gel (transdermal), Prasco Laboratories, effective 2024-09-30, section 7 Drug Interactions, via openFDA","quote":"Androgens may decrease blood glucose and therefore may decrease insulin requirements in diabetic patients … Changes in anticoagulant activity may be seen with androgens … Use of testosterone with adrenocorticotrophic hormone (ACTH) or corticosteroids may result in increased fluid retention.","accessed":"2026-08-27"},{"id":"fda_testo_cyp_int","url":"https://api.fda.gov/drug/label.json?search=openfda.substance_name:%22TESTOSTERONE%22+AND+_exists_:drug_interactions&limit=3","label":"US FDA label — Testosterone Cypionate injection (the molecule in SG's Depo-Testosterone), Bryant Ranch Prepack, effective 2025-11-12, Drug interactions, via openFDA","quote":"Androgens may increase sensitivity to oral anticoagulants … Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone. In diabetic patients, the metabolic effects of androgens may decrease blood glucose","accessed":"2026-08-27"}],"brand_certs":null,"updated_at":"2026-08-29T16:16:33.302383+08:00"},"disclaimer":"kozen-x is not a medical device and does not give medical advice. it lists what published sources have written down. absence of a record is not the same as safe."}